iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
1.320
-0.070 (-5.04%)
At close: Nov 7, 2025, 4:00 PM EST
1.301
-0.019 (-1.46%)
After-hours: Nov 7, 2025, 7:59 PM EST
iBio, Inc. Employees
iBio, Inc. had 20 employees as of June 30, 2025. The number of employees increased by 4 or 25.00% compared to the previous year.
Employees
20
Change (1Y)
4
Growth (1Y)
25.00%
Revenue / Employee
$20,000
Profits / Employee
-$918,850
Market Cap
26.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 20 | 4 | 25.00% |
| Jun 30, 2024 | 16 | -10 | -38.46% |
| Jun 30, 2023 | 26 | -80 | -75.47% |
| Jun 30, 2022 | 106 | 31 | 41.33% |
| Jun 30, 2021 | 75 | 24 | 47.06% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IBIO News
- 9 days ago - iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance - GlobeNewsWire
- 16 days ago - iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 18 days ago - iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025 - GlobeNewsWire
- 2 months ago - iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - iBio Announces Closing of $50 Million Public Offering - GlobeNewsWire
- 2 months ago - iBio Announces Pricing of $50 Million Public Offering - GlobeNewsWire
- 2 months ago - iBio Announces Proposed Public Offering - GlobeNewsWire
- 4 months ago - iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results - GlobeNewsWire